Examining valganciclovir prophylaxis duration among high-risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort

Transpl Infect Dis. 2021 Aug;23(4):e13581. doi: 10.1111/tid.13581. Epub 2021 Feb 18.
No abstract available

Keywords: cytomegalovirus; heart transplant; valganciclovir.

Publication types

  • Letter

MeSH terms

  • Antiviral Agents / therapeutic use
  • Ganciclovir / therapeutic use
  • Heart Transplantation* / adverse effects
  • Humans
  • Retrospective Studies
  • Tissue Donors
  • Transplant Recipients*
  • Valganciclovir / therapeutic use

Substances

  • Antiviral Agents
  • Valganciclovir
  • Ganciclovir